Biotest AG: Biotest establishes basis for significantly higher earnings potentia
News: Biotest AG / Key word(s): 9-month figures / Biotest establishes basis for significantly higher earnings potential - Profitable core business despite setback in Q3 2015 - Focus on core business increases planning reliability - Good progress of plasma protein development projects Dreieich, 10 November 2015. At today's analyst conference in Frankfurt am Main, the Board of Management will discuss how the continued profitable growth of Biotest's business will be ensured and which measures will contribute to the growth. These include: - The expansion of the product portfolio from three to five products while simultaneously doubling production capacity will improve the competitive position and the profitability of Biotest. - Focusing research activities on plasma proteins while continuing ongoing research and development activities for monoclonal antibodies until successful partnering will lower the risk of Biotest's business model and thereby increase planning reliability. - Another key aspect for the near future will be the increase of production at the US subsidiary Biotest Pharmaceuticals Corp. (BPC), Boca Raton, USA, where the not fully utilised production capacities and substantially decreased marketing prospects for the Civacir project required the recognition of impairments totalling The expansion of the plasma product portfolio will significantly increase Biotest's future earnings potential. A considerable contribution to achieve this will be the focus on the plasma business, the stabilisation of the company's US business with improved capacity utilization, strict cost management and increased cooperation with partners. In the first nine months of 2015, the Biotest Group generated slightly higher revenues of EUR 417.9 million (+2% year-on-year), but reported negative earnings of EUR -82 million due to impairments, as already announced. For the fourth quarter Biotest expects a positive EBIT in the range of EUR 5 million to EUR 10 million. For the total year 2015 the Board of Management anticipates a positive operative cash flow and gives a positive outlook for 2016. The nine-month report is available on the company's website http://www.biotest.de/ww/en/pub/investor_relations/publications/quarterly_reports.cfm.The presentation of today's conference for analysts and journalists is available for download from the website. After the conference, an audio file will be available on the Biotest webpage. Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 2015-11-10 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | Biotest AG | |
| Landsteinerstraße 5 | ||
| 63303 Dreieich | ||
| Germany | ||
| Phone: | 0 61 03 - 8 01-0 | |
| Fax: | 0 61 03 - 8 01-150 | |
| E-mail: | investor_relations@biotest.de | |
| Internet: | http://www.biotest.de | |
| ISIN: | DE0005227235, DE0005227201 | |
| WKN: | 522723, 522720 | |
| Indices: | SDAX | |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart | |
| End of News | DGAP News Service |
| 410653 2015-11-10 |